Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bryan Moline

Internal Medicine Oak Park, IL Medical Doctor

NPI 1720046774 CMS profile 305417

610 S Maple Ave, Suite 2100, Oak Park, IL 60304

Open in the dashboard

General payments

$337

9 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bryan Moline of Oak Park, IL is reported in the CMS Open Payments database as having received $337 across 9 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $92 1
2020 General $132 2
2019 General $113 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bryan Moline
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bryan Moline were reported at $92. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bryan Moline Internal Medicine median Middle half National median
2019 $113 $159 $48–$570 $163
2020 $132 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $92 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $132 7 payments
  2. Gilead Sciences, Inc. $112 1 payment
  3. Novo Nordisk Inc $92 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $337 9 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $132 7 payments
  2. Descovy $112 1 payment
  3. Ozempic $92 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

5,208

Median for Internal Medicine: 777

Drug cost

$347,527

Median for Internal Medicine: $73,373

Branded share of claims

18.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 32 $49,503
Ozempic Semaglutide Brand 20 $33,819
Linzess Linaclotide Brand 37 $31,730
Xarelto Rivaroxaban Brand 36 $31,498
Januvia Sitagliptin Phosphate Brand 31 $29,639
Eliquis Apixaban Brand 34 $26,212
Mounjaro Tirzepatide Brand 24 $25,395
Wegovy Semaglutide Brand 14 $21,015
Breo Ellipta Fluticasone/Vilanterol Brand 18 $8,707
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $8,613

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$172,850

Of which drugs: $29,772

Medicare patients

339

Average age 75

Services billed

2,160

139 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 44%
Ischemic heart disease 30%
Diabetes 25%
Depression 24%
Osteoporosis 23%
Cancer 20%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 96 113 $17,115
Vaccine for influenza for injection into muscle 90653 Office 97 97 $7,937
Pcv20 vaccine im 90677 Office 14 14 $4,062

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record